The BD® Flu+ Syringe has been developed with minimal waste space in order to maximise vaccine dose availability and increase the number of people who can be vaccinated.
true
Support
Turkey
+90 216 680 10 02
+90 216 680 16 55
CC_Turkey@bd.com
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Middle East & North Africa
+971 4 5592555
+971 4 5592599
info_uae@bd.com
Saudi Arabia
+966 11 472 7933
+966 11 472 3387
Saudi_info@bd.com
Egypt
Becton Dickinson BV, Scientific Office Mivida Business Park, Building A2, 1st Floor, Office 107, New Cairo, Cairo, Egypt.
- Overview
- EIFU & Resources
true
Low dead-volume syringes are engineered to increase the available amount of vaccine by minimizing vaccine waste.1,2
Vaccine can only be administered with appropriate medical devices or prefilled delivery systems.3
Low dead-volume syringes can play an essential role in expanding available vaccine doses during a pandemic.
The total cost of injection devices with low dead-volume is more than offset by the savings associated with lower vaccine waste.
Dose sparing plunger:
The syringe is designed to minimize vaccine waste
ISO color-coded plunger rod:
Facilitates quick identification of needle gauge
Clear barrel:
- With variable-dose scale markings
Other Features:
- Pre-attached needle
- Sterile, single-use
- Natural Rubber Latex is not part of the material formulation
true
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
Case Studies
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Learn more
true
Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.
References
- Data on file at BD. TEST-001664-29, BDMS, 2004.
- Strauss K. et al. Pandemic influenza preparedness: The critical role of the syringe. Vaccine 24; 2006, 4874–4882
- US Pharmacopeia Industry Standards recommend vial overfill up to 25% for influenza vaccine.
BD-25579
true